Next Article in Journal
Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study
Next Article in Special Issue
Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
Previous Article in Journal
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Previous Article in Special Issue
Major Complex Trait for Early De Novo Programming ‘CoV-MAC-TED’ Detected in Human Nasal Epithelial Cells Infected by Two SARS-CoV-2 Variants Is Promising to Help in Designing Therapeutic Strategies
Article

Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography

1
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
2
Institute of Translational Medicine and Biotechnology, Sechenov Moscow State Medical University, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
Academic Editor: Luis Martinez-Sobrido
Vaccines 2022, 10(6), 949; https://doi.org/10.3390/vaccines10060949
Received: 25 April 2022 / Revised: 8 June 2022 / Accepted: 9 June 2022 / Published: 15 June 2022
(This article belongs to the Special Issue Advances in COVID-19 Vaccines Development)
Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones, have been developed and approved for clinical use worldwide. Inactivated vaccines are produced using a proven technology that is widely used for the production of vaccines for the prevention and control of infectious diseases, including influenza and poliomyelitis. The development of inactivated whole-virion vaccines commonly includes several stages: the production of cellular and viral biomass in cell culture; inactivation of the virus; filtration and ultrafiltration; chromatographic purification of the viral antigen; and formulation with stabilizers and adjuvants. In this study, the suitability of four resins for Size-Exclusion Chromatography was investigated for the purification of a viral antigen for the human COVID-19 vaccine. View Full-Text
Keywords: vaccine; Size-Exclusion Chromatography; COVID-19; chromatography; SARS-CoV-2; resin vaccine; Size-Exclusion Chromatography; COVID-19; chromatography; SARS-CoV-2; resin
Show Figures

Figure 1

MDPI and ACS Style

Kovpak, A.A.; Piniaeva, A.N.; Gerasimov, O.A.; Tcelykh, I.O.; Ermakova, M.Y.; Zyrina, A.N.; Danilov, D.V.; Ivin, Y.Y.; Kozlovskaya, L.I.; Ishmukhametov, A.A. Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography. Vaccines 2022, 10, 949. https://doi.org/10.3390/vaccines10060949

AMA Style

Kovpak AA, Piniaeva AN, Gerasimov OA, Tcelykh IO, Ermakova MY, Zyrina AN, Danilov DV, Ivin YY, Kozlovskaya LI, Ishmukhametov AA. Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography. Vaccines. 2022; 10(6):949. https://doi.org/10.3390/vaccines10060949

Chicago/Turabian Style

Kovpak, Anastasia A., Anastasia N. Piniaeva, Oleg A. Gerasimov, Irina O. Tcelykh, Mayya Y. Ermakova, Anna N. Zyrina, Dmitry V. Danilov, Yury Y. Ivin, Liubov I. Kozlovskaya, and Aydar A. Ishmukhametov. 2022. "Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography" Vaccines 10, no. 6: 949. https://doi.org/10.3390/vaccines10060949

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop